Drug Profile

Ropivacaine prolonged release - InSitu Biologics

Alternative Names: INSB-200

Latest Information Update: 31 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator InSitu Biologics
Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
Mechanism of Action Potassium channel antagonists; Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Postoperative pain

Most Recent Events

01 Nov 2021 Preclinical trials in Pain in USA (Parenteral) (InSitu Biologics pipeline, November 2021).
01 Nov 2021 Preclinical trials in Postoperative pain in USA (Parenteral) (InSitu Biologics pipeline, November 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com